Kala Bio (KALA) Receivables - Other (2019 - 2026)
Kala Bio (KALA) posted Receivables - Other of $74000.0 for Q1 2026, up 825.0% sequentially from $8000.0 in Q3 2025, and down 25.25% YoY from $99000.0 in Q1 2025.
Kala Bio (KALA) Receivables - Other (2019 - 2026) Analysis & Trends
Kala Bio has reported Receivables - Other for 8 years, with the latest figure at $74000.0 in Q1 2026.
- Quarterly Receivables - Other fell 25.25% year-over-year to $74000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74000.0 (down 25.25% YoY) and the FY2024 annual result came in at $99000.0, down 16.81% from the prior year.
- Receivables - Other rose to $74000.0 in Q1 2026 per KALA's latest filing, from $8000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $280000.0 in Q1 2023 and troughed at $8000.0 in Q3 2025.
- A 5-year average of $114000.0 and a median of $112000.0 in 2025 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2022 and 2023: Receivables - Other tumbled 98.77% in 2022, then jumped 357.69% in 2023.
- Over 5 years, Receivables - Other stood at $26000.0 in 2022, then surged by 357.69% to $119000.0 in 2023, then decreased by 16.81% to $99000.0 in 2024, then tumbled by 91.92% to $8000.0 in 2025, then soared by 825.0% to $74000.0 in 2026.
- According to Business Quant data, Receivables - Other over the past three periods registered $74000.0, $8000.0, and $112000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Kala Bio | 9.97 Mn | 9.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 112,000.00 |
| Jun 30, 2025 | 112,000.00 |
| Mar 31, 2025 | 99,000.00 |
| Mar 31, 2025 | 99,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Jun 30, 2024 | 117,000.00 |
| Jun 30, 2024 | 117,000.00 |
| Dec 31, 2023 | 119,000.00 |
| Dec 31, 2023 | 119,000.00 |
| Sep 30, 2023 | 143,000.00 |
| Sep 30, 2023 | 143,000.00 |
| Jun 30, 2023 | 177,000.00 |
| Jun 30, 2023 | 177,000.00 |
| Mar 31, 2023 | 280,000.00 |
| Mar 31, 2023 | 280,000.00 |